http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2879675-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a799d17d5f808bee28dc9a15345a54f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b3eb3561524efa2868aa46dba62783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9334d6d396c199f51b2a83b5b0ae25b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25501c4c664a144057ad1caf1217d9e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e63bbd19fa0c7fb0a29ba8c051abc91 |
| publicationDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2879675-T3 |
| titleOfInvention | Pharmaceutical composition of 5-HT6 antagonist |
| abstract | An immediate release pharmaceutical composition, which over a total of 100% by weight comprises: a) from 2% to 60% of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof; b) from 36% to 97% diluent or a total of two diluents; wherein the diluent is selected from the group consisting of microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate, lactose, lactose hydrate, lactose anhydrate, mannitol, starch, and isomaltol; c) from 0.5% to 2% of lubricant; wherein the lubricant is magnesium stearate; d) from 0.5% to 1% slip agent; wherein the slip agent is colloidal silicon dioxide; e) 0% to 10% binder; wherein the binder is selected from the group consisting of povidone or hydroxypropyl methylcellulose; f) 0% to 5% disintegrating agent; wherein the disintegrating agent is selected from crospovidone, sodium starch glycolate and croscarmellose sodium; and g) 0% to 2% acidifying agent; wherein the acidifying agent is citric acid. |
| priorityDate | 2016-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.